Shares of Athersys, which have nearly doubled in the past 3 months, should keep their momentum as a number of data points concerning the company’s regenerative medicine treatments roll in, says Gil Van Bokkelen, CEO of Athersys. Van Bokkelen says the company’s lead drug MultiStem is entering into a number of late stage clinical trials across a number of illnesses. He also says the company is making huge strides with patents in Japan and has successfully raised enough cash to carry it forward.
Subscribe to TheStreetTV on YouTube:
For more content from TheStreet visit:
Check out all our videos:
Follow TheStreet on Twitter:
Like TheStreet on Facebook:
Follow TheStreet on LinkedIn:
Follow TheStreet on Google+:
source
